PDF herunterladen
Frauenheilkunde up2date 2013; 7(6): 423-434
DOI: 10.1055/s-0033-1346893
Allgemeine Gynäkologie und gynäkologische Onkologie
Georg Thieme Verlag KG Stuttgart · New York

Palliative Konzepte beim Ovarialkarzinom

Günter Emons
,
Gerd J. Bauerschmitz
,
Martin Hellriegel
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
19. Dezember 2013 (online)

Auch verfügbar auf
    Lizenzen und Reprints Alle Artikel dieser Rubrik
Kernaussagen

Trotz deutlicher Verbesserungen in der Therapie stirbt die Mehrzahl der Ovarialkarzinompatientinnen an dieser Erkrankung. Das Behandlungsteam muss beim platinrefraktären/platinresistenten OC rechtzeitig den Einsatz wenig wirksamer bzw. unwirksamer Chemotherapien zurücknehmen und stattdessen professionell die sehr beeinträchtigenden Symptome der fortschreitenden OC-Erkrankung hinauszögern bzw. behandeln. Eine enge Kooperation zwischen gynäkologischen Onkologen und Palliativmedizinern ist hierfür die Voraussetzung.

 

  • Literatur

  • 1 ECO, European Cancer Observatory. http://
  • 2 Lawrie TA, Bryant A, Cameron A et al. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev 2013; (7) CD006910 DOI: 10.1002/14651858.CD006910.pub2.
    Google Scholar
  • 3 Colombo N, Kutarska E, Dimopoulos M et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012; 30: 3841-3847
    CrossrefGoogle Scholar
  • 4 Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e.V. und Deutschen Krebshilfe e.V., Hrsg. S3-Leitlinie, Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren. München: W. Zuckschwerdt Verlag; 2013
    CrossrefGoogle Scholar
  • 5 Hanker LC, Loibl S, Burchardi N et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 2012; 23: 2605-2612
    CrossrefPubMedGoogle Scholar
  • 6 Elit L, Hirte H. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. Onco Targets Ther 2013; 6: 107-118
    Google Scholar
  • 7 Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 (Suppl. 01) S161-S192
    CrossrefGoogle Scholar
  • 8 Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med 2011; 364: 2060-2065
    CrossrefGoogle Scholar
  • 9 Peppercorn JM, Smith TJ, Helft PR et al. American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 2011; 29: 755-760
    CrossrefGoogle Scholar
  • 10 Friedlander M, Butow P, Stockler M et al. Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. Int Ja Gynecol Cancer 2009; 19 (Suppl. 02) S44-S48
    Google Scholar
  • 11 Emons G. Endokrine Therapie. In: Kreienberg R, du Bois A, Pfisterer J, et al., Hrsg Management des Ovarialkarzinoms. Heidelberg: Springer; 2009: 208-212
    CrossrefGoogle Scholar
  • 12 Radwany SM, von Gruenigen VE. Palliative and end-of-life care for patients with ovarian cancer. Clinical Obstet Gynecol 2012; 55: 173-184
    Google Scholar
  • 13 Nappa U, Lindqvist O, Rasmussen BH et al. Palliative chemotherapy during the last month of life. Ann Oncol 2011; 22: 2375-2380
    CrossrefGoogle Scholar
  • 14 von Gruenigen VE, Daly BJ. Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol 2005; 97: 638-644
    CrossrefGoogle Scholar
  • 15 Braga S. Why do our patients get chemotherapy until the end of life?. Ann Oncol 2011; 22: 2345-2348
    CrossrefPubMedGoogle Scholar
  • 16 Shoemaker LK, Estfan B, Induru R et al. Symptom management: an important part of cancer care. Cleveland Clinic J Med 2011; 78: 25-34
    CrossrefGoogle Scholar
  • 17 Klein C, Eckl S, Ostgathe C. Schmerztherapie bei der onkologischen Patientin und in der Palliativmedizin. Frauenheilkunde up2date 2013; 2: 103-118
    Artikel in Thieme ConnectGoogle Scholar
  • 18 Rezk Y, Timmins 3rd PF, Smith HS. Review article: palliative care in gynecologic oncology. Am J Hospice Palliative Care 2011; 28: 356-374
    CrossrefGoogle Scholar
  • 19 Mayer-Hope JM, Pothuri B. The role of palliative surgery in gynecologic cancer cases. Oncologist 2013; 18: 73-79
    CrossrefGoogle Scholar
  • 20 Pothuri B, Meyer L, Gerardi M et al. Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma. Gynecol Oncol 2004; 95: 193-195
    CrossrefGoogle Scholar
  • 21 Caceres A, Zhou Q, Iasonos A et al. Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series. Gynecol Oncol 2008; 108: 482-485
    CrossrefGoogle Scholar
  • 22 Pothuri B, Montemarano M, Gerardi M et al. Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol 2005; 96: 330-334
    CrossrefPubMedGoogle Scholar
  • 23 Diver E, OʼConnor O, Garrett L et al. Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement. Gynecol Oncol 2013; 129: 332-335
    CrossrefGoogle Scholar
  • 24 Rath KS, Loseth D, Muscarella P et al. Outcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer. Gynecol Oncol 2013; 129: 103-106
    CrossrefGoogle Scholar
  • 25 Hisanaga T, Shinjo T, Morita T et al. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Japanese J Clin Oncol 2010; 40: 739-745
    Google Scholar
  • 26 Kucukmetin A, Naik R, Galaal K et al. Palliative surgery versus medical management for bowel obstruction in ovarian cancer. Cochrane Database Syst Rev 2010; (7) CD007792 DOI: 10.1002/14651858.CD007792.pub2.
    Google Scholar
  • 27 Leitlinienprogramm Onkologie der AWMF, Deutsche Krebsgesellschaft e. V. und Deutsche Krebshilfe e.V., Hrsg. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. München: W. Zuckschwerdt Verlag; 2012
    CrossrefGoogle Scholar
  • 28 Harding V, Fenu E, Medani H et al. Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer. Br J Cancer 2012; 107: 925-930
    CrossrefPubMedGoogle Scholar